Description
The National Cancer Institute (NCI) is seeking to accelerate the adoption and validation of molecular/cellular/imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment. This opportunity will support the clinical validation of established assays for up to 3 years using specimens from retrospective or prospective clinical trials or studies. The project requires multi-disciplinary interaction and collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists.
• The opportunity is open to various types of applicants, including institutions of higher education, non-profits, and small businesses.
• The award ceiling is $250,000.
• The project duration is up to 3 years.
• The opportunity is not intended to support early-stage development of technology or the conduct of clinical trials.